Dexmedetomidine in Children Having Transthoracic Echocardiography
2017年7月28日 更新者:Children's Hospital Medical Center, Cincinnati
A Qualitative Comparison of Oral Chloral Hydrate vs 2.0 or 3.0 mcg/kg Nasal Dexmedetomidine in Children Undergoing Transthoracic Echocardiography
Sedation Techniques for children undergoing transthoracic echocardiography (TTE).
研究概览
详细说明
The goal in this study is to determine if there is a significant difference in the quality of sedation between two standard sedation techniques and between two doses of dexmedetomidine for children undergoing (TTE).
研究类型
介入性
注册 (实际的)
279
阶段
- 第四阶段
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
-
Shanghai、中国
- Shanghai Children's Hospital
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
3个月 至 3年 (孩子)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- Outpatients scheduled to receive sedation for transthoracic echocardiography
- Subject must be a candidate for both types of anesthetic and both doses of dexmedetomidine
- Must be 3 months to 36 months of age
Exclusion Criteria:
- The subject has a history of cardiac conduction system disease (e.g. 1st or 2nd degree AV block) or channelopathy (e.g. long QT).
- The subject is taking digoxin, alpha-adrenergic or beta-adrenergic agonist or antagonist (e.g., clonidine, propranolol, albuterol), anti-arrhythmic medications, or vasodilators (e.g. ACE inhibitors)
- The subject has received a dose of any other sedative within 48 hours.
- The subject has life-threatening, medical conditions (American Society of Anesthesiologists Physical Status 4, 5). The American Society of Anesthesiologists (ASA) classification scale is a measure of physical status or how healthy the patient is. For our study, we will focus on children which are defined as ASA I, II or III which means a healthy child (ASA I), a child with a systemic disease that is mild and well controlled (ASA II) or a child with systemic disease that is severe and controlled (ASA III).
- The subject is allergic to or has a contraindication to any of the drugs used in the study.
- The subject has previously been treated under this protocol.
- The subject has severe coarctation of the aorta (risk of exaggerated vasoconstriction)
- The subject has Moyamoya disease (risk of recurrent stroke)
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Chloral Hydrate + placebo
Oral chloral hydrate sedation in flavored syrup plus nasal saline placebo
|
70mg/kg chloral hydrate
Flavored placebo syrup
|
|
有源比较器:Dexmedetomidine 2mcg/kg + placebo
Nasal dexmedetomidine sedation 2 mcg/kg plus oral flavored syrup placebo
|
Flavored placebo syrup
2mcg/kg
3mcg/kg
|
|
有源比较器:Dexmedetomidine 3mcg/kg + placebo
Nasal dexmedetomidine sedation 3 mcg/kg plus oral flavored syrup placebo
|
Flavored placebo syrup
2mcg/kg
3mcg/kg
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Time to sedation
大体时间:30 minutes
|
Achieve Ramsay sedation >3 within 30 minutes of administration of drug
|
30 minutes
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Duration of sedation level >3
大体时间:Patients will be followed for the duration of the procedure, average of 1 hour
|
Patients will be followed for the duration of the procedure, average of 1 hour
|
|
|
The number of sonographer pauses
大体时间:Participants will be followed for the duration of the procedure, average of 1 hour
|
The number of sonographer pauses over 2 minutes due to patient movement or medical interventions will be counted
|
Participants will be followed for the duration of the procedure, average of 1 hour
|
|
Need for rescue dexmedetomidine
大体时间:Participants will be followed for the duration of the procedure, average of 1 hour
|
The incidence of need for rescue nasal dexmedetomidine, due to patient arousal or movement prior to completion of TTE.
|
Participants will be followed for the duration of the procedure, average of 1 hour
|
|
Incidence of respiratory complications
大体时间:Participants will be followed for the duration of the hospital stay, average of 2 hours
|
Documentation of the incidence of respiratory complications
|
Participants will be followed for the duration of the hospital stay, average of 2 hours
|
|
Vital sign deviations of more than 30% from baseline
大体时间:Participants will be followed for the duration of the hospital stay, average of 2 hours
|
Documentation of the incidence of blood pressure or heart rate deviations of more than 30% from baseline.
Baseline will be measured prior to sedative administration.
|
Participants will be followed for the duration of the hospital stay, average of 2 hours
|
|
Post anesthesia drowsiness
大体时间:Participants will be followed for the duration of the post procedure stay, average of 1 hour
|
Documentation of the incidence of post anesthesia drowsiness
|
Participants will be followed for the duration of the post procedure stay, average of 1 hour
|
|
Duration of Post Anesthesia Care Unit phase
大体时间:Participants will be followed for the duration of the post procedure stay, average of 1 hour
|
Documentation of the stay in Post Anesthesia Care Unit in minutes
|
Participants will be followed for the duration of the post procedure stay, average of 1 hour
|
|
Time to oral fluid intake
大体时间:Participants will be followed for the duration of the post procedure stay, average of 1 hour
|
Documentation of the time (in minutes) to oral fluid intake during the PACU phase
|
Participants will be followed for the duration of the post procedure stay, average of 1 hour
|
|
Time to discharge
大体时间:Participants will be followed for the duration of the post procedure stay, average of 1 hour
|
Documentation of the hospital stay after completion of the TTE.
|
Participants will be followed for the duration of the post procedure stay, average of 1 hour
|
|
Satisfaction of parents
大体时间:Up to 3 days
|
The satisfaction of the sedation technique will be completed by the parents by asking a series of questions during a follow-up phone call the next business day after the TTE.
|
Up to 3 days
|
|
Severity of respiratory complications
大体时间:Participants will be followed for the duration of the hospital stay, average of 2 hours
|
Documentation of the severity of respiratory complications
|
Participants will be followed for the duration of the hospital stay, average of 2 hours
|
|
Post anesthesia agitation
大体时间:Participants will be followed for the duration of the post procedure stay, average of 1 hour
|
Documentation of the incidence of post anesthesia agitation
|
Participants will be followed for the duration of the post procedure stay, average of 1 hour
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:Jeffrey Miller, MD、Children's Hospital Medical Center, Cincinnati
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2014年9月1日
初级完成 (实际的)
2017年5月1日
研究完成 (实际的)
2017年5月1日
研究注册日期
首次提交
2015年7月27日
首先提交符合 QC 标准的
2015年8月13日
首次发布 (估计)
2015年8月14日
研究记录更新
最后更新发布 (实际的)
2017年7月31日
上次提交的符合 QC 标准的更新
2017年7月28日
最后验证
2017年7月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.